Literature DB >> 17150838

An apoptotic pathway of 3'-Ethynylcytidine(ECyd) involving the inhibition of RNA synthesis mediated by RNase L.

Tomoharu Naito1, Tatsushi Yokogawa, Hye-Sook Kim, Akira Matsuda, Takuma Sasaki, Masakazu Fukushima, Yukio Kitade, Yusuke Wataya.   

Abstract

RNase L is an endoribonuclease that requires 2'-5' oligoadenylate to cleave single-stranded RNA. Although the antiviral effects of RNase L are well known because of its viral RNA degradation activity recently but it has been suggested that RNase L is concerned in mitochondrial-caspase dependent apoptotic signaling pathway induced by a number of anticancer agents. Moreover, it has variety of functions including translation and transcription of proteins. In this report, we found that 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd), which inhibits RNA synthesis through competitive inhibition of RNA polymerase I induced 28S rRNA fragmentation. The cleavage pattern of rRNA induced by ECyd was similar and the cleavage sites were identical to those cleaved by RNase L. Additionaly, apoptosis induced by ECyd was elevated following the protein expression of RNase L in the tumor cells when treated with IFN-alpha2a which was known to induce RNase L expression. To identify the role of RNase L in apoptosis induced by ECyd, we detected the decreased level of RNase L by several folds in the tumor cell lines through a small interfering RNA (siRNA). These results indicated that RNase L might integrate apoptotic signals induced by ECyd and provide the possibility to be a novel clinical target for cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150838     DOI: 10.1093/nass/nrl051

Source DB:  PubMed          Journal:  Nucleic Acids Symp Ser (Oxf)        ISSN: 0261-3166


  1 in total

1.  A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.

Authors:  Shunsuke Meike; Tohru Yamamori; Hironobu Yasui; Masato Eitaki; Akira Matsuda; Masami Morimatsu; Masakazu Fukushima; Yasundo Yamasaki; Osamu Inanami
Journal:  Mol Cancer       Date:  2011-07-28       Impact factor: 27.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.